Trials / Terminated
TerminatedNCT00100737
Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)
A Phase 2 Randomized, Open-Label, Controlled Trial of the Addition of 8 Weeks SC Administration of Aldesleukin (Rh-Interleukin-2 [IL-2]) to 4 Weeks of IV Administration of Rituximab in the Treatment of Rituximab Naïve Subjects With Follicular Non-Hodgkin's Lymphoma, Refractory or Relapsed After Previous Chemotherapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 300 (planned)
- Sponsor
- Chiron Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether interleukin-2 given 3 times weekly for 8 weeks in combination with rituximab is effective and safe when compared to rituximab given alone in the treatment of follicular NHL subjects that have never received rituximab as a treatment and are refractory or relapsed after previous chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | interleukin-2 | |
| DRUG | rituximab |
Timeline
- First posted
- 2005-01-07
- Last updated
- 2006-02-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00100737. Inclusion in this directory is not an endorsement.